Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) – After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8....
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas...
A director at CNA Financial Corp sold 23,301 shares at 44.780USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 ...
Arvinas to Present at Upcoming Investor Conferences NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presen...
NEW YORK--(BUSINESS WIRE)-- New Mountain Finance Corporation (NASDAQ: NMFC) (“New Mountain,” “New Mountain Finance” or the “Company”) today announced its financial results for the quarter ended March 31, 2024. First Quarter Highlights1 Net investment income of $37.3 million, or $0.36 per weighted average share Net asset value of $12.77 per share compared to $12.87 per share as of December 31, 2023. The 0.8% decline is driven by stable core credit performance, offset by a decrease in value in one of the Company's equity positions Internal risk rating improved with 96.5% of the portfo...
TBK Bank Appoints Jamie Paterson as EVP, Chief Operating Officer - Banking Operations DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) announced today the appointment of Jamie Paterson as the executive vice president, chief operating officer – banking operations of its TBK Bank, SSB subsidiary. In his role, Paterson will be responsible for overseeing operational excellence for the bank. Reporting to Todd Ritterbusch, president of TBK Bank, Paterson will provide direction and oversight of all operational functions within the retail bank, including digital b...
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston,...
Triumph Financial to Live Stream Annual Meeting DALLAS, April 22, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (NASDAQ:TFIN) (“the Company”) will be holding its Annual Meeting of Stockholders on April 23, 2024 at 8:30 AM central time. The Company will host a live webcast of the annual meeting. A simultaneous view-only webcast may be accessed via the Company's website at , or through a direct link here at: About Triumph Triumph Financial, Inc. (Nasdaq: TFIN) is a financial holding company focused on payments, factoring and banking. Headquartered in Dallas, Texas, its diversified ...
Lakeland Bancorp Announces First Quarter Results OAK RIDGE, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Lakeland Bancorp, Inc. (NASDAQ: LBAI) (the “Company”), the parent company of Lakeland Bank (“Lakeland”), reported net income of $19.8 million and earnings per diluted share ("EPS") of $0.30 for the three months ended March 31, 2024 compared to net income of $19.8 million and diluted EPS of $0.30 for the three months ended March 31, 2023. For the first quarter of 2024, annualized return on average assets was 0.73%, annualized return on average common equity was 6.79% and annualized return o...
Triumph Financial Releases First Quarter 2024 Financial Results DALLAS, April 17, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) has released its first quarter 2024 financial results. The 1Q 2024 financial results and shareholder letter are available on the Company’s website at through the News & Events, Events & Presentations links. Aaron P. Graft, Vice Chairman & CEO, and Brad Voss, CFO, will review the financial results in a conference call with investors and analysts beginning at 9:30 a.m. central time on Thursday, April 18, 2024. The live video conference option m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.